第十一批国家组织药品集采报量启动 优化规则满足群众多元用药需求

Core Points - The eleventh batch of national organized drug procurement has officially started, with new reporting rules introduced to enhance the procurement process and meet diverse public medication needs [1][2] - Medical institutions are required to report their procurement needs from August 6 to August 25, 2023, and must participate in the reporting process as per government regulations [1][2] - The new reporting rules allow institutions to report by brand name, which respects clinical choices and addresses patient concerns about brand preferences [1][2] Reporting Rules - Medical institutions can report either by drug name or by specific brand, with no limit on the number of brands that can be reported [1][2] - If a reported brand is not selected, the procurement responsibility will shift to the main supplier in the province, and institutions must fulfill the agreement quantity with that supplier [2] - Institutions must ensure that total reported quantities are not less than 80% of the average procurement volume for 2023 and 2024 [2][3] Clinical Demand Considerations - Institutions are encouraged to report quantities based on actual clinical needs, with specific guidelines for drugs with increasing usage trends [2][3] - For drugs with uncertain demand, such as those related to seasonal diseases, institutions can adjust their reported quantities accordingly [3] - Institutions are allowed to reduce reported quantities for drugs with expected lower usage due to departmental adjustments or temporary needs [3] Procurement Principles - The procurement process will adhere to principles of maintaining clinical stability, ensuring quality, preventing collusion, and avoiding excessive competition [4] - Companies are advised to conduct cost-benefit analyses and engage in rational pricing while resisting illegal practices such as collusion [4] Historical Context - Since 2018, ten batches of national organized drug procurement have resulted in the purchase of 435 types of drugs, contributing to reduced costs for patients and facilitating the inclusion of new drugs in the medical insurance catalog [3]